Related Stories
-
Ascension St. Vincent says it has restored electronic records system hit by May cyberattack
-
Researchers say money alone isn’t enough to overcome public health workforce woes
-
IU Health to eliminate noncompete clauses for primary-care docs
-
Senator’s letter critical of hospital association casts shadow on 2025 health care discussions
-
Michigan’s largest insurer to drop weight-loss drug coverage
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now- 0.25
- 0.50
- 0.75
- 1.00
- 1.25
- 1.50
- 1.75
- 2.00
Erin Fox has tracked drug shortages for more than 20 years, and she sees no easy solutions for what has become a record run.
Total active shortages hit an all-time high of 323 in this year’s first quarter, according to the University of Utah Drug Information Service. That’s up about 86% from a 10-year low of 174 last reached in 2017.
There were 48 new shortages recorded this year through March, according to the data, published by the American Society of Health-System Pharmacists.
Still, Fox also sees positive news developing. The associate chief pharmacy officer at University of Utah Health spoke recently with The Associated Press. The conversation has been edited for clarity and length.
Q: Are there any signs that this is letting up?
A: Unfortunately, no. We haven’t necessarily solved some of the root causes.
We have, overall, relatively few manufacturers. (The U.S. Food and Drug Administration) halted inspections during COVID. Now they’re back, at factories that maybe haven’t been inspected for five or six years. They’re finding some things to fix. Those fixes can take anywhere from 6 to 18 months for production to get fully back on schedule.
Meanwhile, other companies don’t necessarily have the capacity to ramp up production to make up the difference.
It’s not the FDA’s fault. We want them to find those quality deficits. But when FDA goes out looking all at once, it can be pretty disruptive.
Q: What are the typical drugs that land on the shortage list?
A: Generic, injectable hospital drugs or older drugs. They are usually pretty low cost. There’s not a lot of resilience in the supply chain for another company to make up the difference.
We saw all those chemotherapy shortages last year in part because a large factory in India, (the FDA) found quality problems there. They made a large amount of the U.S. supply. The other companies were unable to quickly make up the difference.
Things have definitely improved, but that factory is still not running.
Q: What is one thing about shortages that patients underestimate?
A: They shouldn’t automatically assume they won’t be able to get that treatment.
It might be delayed or they might have to take a capsule instead of a pill. They might have to call their insurance company to ask if they will cover the brand because sometimes (that) is available while the generic is not.
Don’t panic. It’s frustrating to have to do a little bit of work, but usually you will still be able to get a treatment.
Q: Is there any good news?
A: Last year, Congress held four hearings on shortages. They’re still very interested. People are really starting to talk about doing hard work both on the policy side but also maybe a little bit of Congressional action to really try to move this problem forward.
I’ve been leading our efforts to provide data on drug shortages since 2001. This is truly the most interest I’ve ever seen.
Please enable JavaScript to view this content.
You can’t have it both ways. Can’t have dirt cheap products that nobody wants to manufacture because they don’t make a profit. These are businesses that have to make a profit to survive.